|
|
|
|
|
Detail |
| hsa-miR-210 |
|
Unspecified |
Distinctive patterns of microRNA expression in primary muscular disorders. |
2007 |
|
|
|
|
|
|
| hsa-miR-210 |
|
Unspecified |
Distinctive patterns of microRNA expression in primary muscular disorders. |
2007 |
|
|
|
|
|
|
| hsa-miR-210 |
|
Unspecified |
Distinctive patterns of microRNA expression in primary muscular disorders. |
2007 |
|
|
|
|
|
|
| hsa-miR-210 |
|
Unspecified |
Distinctive patterns of microRNA expression in primary muscular disorders. |
2007 |
|
|
|
|
|
|
| hsa-miR-210 |
|
Unspecified |
Distinctive patterns of microRNA expression in primary muscular disorders. |
2007 |
|
|
|
|
|
|
| hsa-miR-210 |
|
Unspecified |
Distinctive patterns of microRNA expression in primary muscular disorders. |
2007 |
|
|
|
|
|
|
| hsa-miR-210 |
|
Unspecified |
MicroRNA expression profiling in prostate cancer. |
2007 |
|
|
|
|
|
|
| hsa-miR-210 |
|
Unspecified |
MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. |
2007 |
|
|
|
|
|
|
| hsa-miR-210 |
|
Unspecified |
MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. |
2007 |
|
|
|
|
|
|
| hsa-miR-210 |
|
Unspecified |
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. |
2006 |
|
|
|
|
|
|
| hsa-miR-210 |
|
Unspecified |
High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. |
2007 |
|
|
|
|
|
|
| hsa-miR-210 |
|
Unspecified |
MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. |
2007 |
|
|
|
|
|
|
| hsa-miR-210 |
|
Unspecified |
MicroRNA gene expression deregulation in human breast cancer. |
2005 |
|
|
|
|
|
|
| hsa-miR-210 |
|
Unspecified |
MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. |
2007 |
|
|
|
|
|
|
| hsa-miR-210 |
|
Unspecified |
Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. |
2008 |
|
|
|
|
|
|
| hsa-miR-210 |
|
Unspecified |
hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. |
2008 |
|
|
|
|
|
|
| hsa-miR-210 |
|
Unspecified |
Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. |
2008 |
|
|
|
|
|
|
| hsa-miR-210 |
|
Unspecified |
Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. |
2009 |
|
|
|
|
|
|
| hsa-miR-210 |
|
Unspecified |
MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer. |
2009 |
|
|
|
|
|
|
| hsa-miR-210 |
|
Causal |
Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation |
2009 |
|
|
|
|
|
|
| hsa-miR-210 |
|
Unspecified |
MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma |
2009 |
|
|
|
|
|
|
| hsa-miR-210 |
|
Unspecified |
MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. |
2008 |
|
|
|
|
|
|
| hsa-miR-210 |
|
Unspecified |
MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. |
2008 |
|
|
|
|
|
|
| hsa-miR-210 |
|
Unspecified |
miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. |
2008 |
|
|
|
|
|
|
| hsa-miR-210 |
|
Causal |
Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer.
|
2008 |
|
|
|
|
|
|
| hsa-miR-210 |
|
Causal |
Transcriptional repression of microRNA genes by PML-RARA increases expression of key cancer proteins in acute promyelocytic leukemia. |
2008 |
|
|
|
|
|
|
| hsa-miR-210 |
|
Unspecified |
Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients. |
2008 |
|
|
|
|
|
|
| hsa-miR-210 |
|
Unspecified |
Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. |
2009 |
|
|
|
|
|
|
| hsa-miR-210 |
|
Unspecified |
Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumours associates with poorer survival. |
2009 |
|
|
|
|
|
|
| hsa-miR-210 |
|
Unspecified |
Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumours associates with poorer survival. |
2009 |
|
|
|
|
|
|
| hsa-miR-210 |
|
Unspecified |
Identification and Functional Characterization of microRNAs Involved in the Malignant Progression of Gliomas |
2009 |
|
|
|
|
|
|